181 related articles for article (PubMed ID: 20297875)
21. The role of the pharmacist in optimizing the use of erythropoietin stimulating agents.
Gebara SN; Moubayed H
J Oncol Pharm Pract; 2010 Mar; 16(1):33-7. PubMed ID: 19401308
[TBL] [Abstract][Full Text] [Related]
22. Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs.
Charytan C
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2355-62. PubMed ID: 21071515
[TBL] [Abstract][Full Text] [Related]
23. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
Pirker R
Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
[TBL] [Abstract][Full Text] [Related]
24. Rebates for anti-anemia drugs draw response from FDA, CMS.
Sipkoff M
Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
[No Abstract] [Full Text] [Related]
25. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
[TBL] [Abstract][Full Text] [Related]
26. Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes.
Agarwal AK; Singh AK
Heart Fail Clin; 2010 Jul; 6(3):323-32. PubMed ID: 20630407
[TBL] [Abstract][Full Text] [Related]
27. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma.
Katodritou E; Dimopoulos MA; Zervas K; Terpos E
Cancer Treat Rev; 2009 Dec; 35(8):738-43. PubMed ID: 19733008
[TBL] [Abstract][Full Text] [Related]
28. Anemia in renal disease: diagnosis and management.
Lankhorst CE; Wish JB
Blood Rev; 2010 Jan; 24(1):39-47. PubMed ID: 19833421
[TBL] [Abstract][Full Text] [Related]
29. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms.
Hadland BK; Longmore GD
J Clin Oncol; 2009 Sep; 27(25):4217-26. PubMed ID: 19636005
[TBL] [Abstract][Full Text] [Related]
30. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
[TBL] [Abstract][Full Text] [Related]
31. Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death.
Costiniuk CT; Camacho F; Cooper CL
Clin Infect Dis; 2008 Jul; 47(2):198-202. PubMed ID: 18532889
[TBL] [Abstract][Full Text] [Related]
32. CERA: third-generation erythropoiesis-stimulating agent.
Topf JM
Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
[TBL] [Abstract][Full Text] [Related]
33. Weighing the hazards of erythropoiesis stimulation in patients with cancer.
Khuri FR
N Engl J Med; 2007 Jun; 356(24):2445-8. PubMed ID: 17568023
[No Abstract] [Full Text] [Related]
34. Strategies for successfully managing the anemia of chronic kidney disease in the long-term care setting.
Germain MJ
Consult Pharm; 2008 Mar; 23 Suppl A():11-7. PubMed ID: 18454575
[TBL] [Abstract][Full Text] [Related]
35. [Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)].
Lovcić V; Vujić J; Ivanac Janković R; Basić-Jukić N; Barisić I; Lovcić P; Dzapo M
Acta Med Croatica; 2009 Sep; 63 Suppl 1():11-6. PubMed ID: 20232547
[TBL] [Abstract][Full Text] [Related]
36. Erythropoiesis-stimulating agents in cancer.
Arcasoy MO
J Clin Oncol; 2008 Jun; 26(18):3097-8; author reply 3098-100. PubMed ID: 18565902
[No Abstract] [Full Text] [Related]
37. Erythropoietic stimulating agents.
Testa U
Expert Opin Emerg Drugs; 2010 Mar; 15(1):119-38. PubMed ID: 20158404
[TBL] [Abstract][Full Text] [Related]
38. Reevaluating erythropoiesis-stimulating agents.
Cotter DJ
N Engl J Med; 2010 May; 362(18):1743; author reply 1743-4. PubMed ID: 20449881
[No Abstract] [Full Text] [Related]
39. Correcting anemia in heart failure: the efficacy and safety of erythropoiesis-stimulating agents.
Lawler PR; Filion KB; Eisenberg MJ
J Card Fail; 2010 Aug; 16(8):649-58. PubMed ID: 20670844
[TBL] [Abstract][Full Text] [Related]
40. Reassessments of ESAs for cancer treatment in the US and Europe.
Bennett CL; McKoy JM; Henke M; Silver SM; MacDougall IC; Birgegård G; Luminari S; Casadevall N; Schellekens H; Sartor O; Lai SY; Armitage JO
Oncology (Williston Park); 2010 Mar; 24(3):260-8. PubMed ID: 20394138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]